Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
- Title
- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
- Author
- 이동윤
- Keywords
- Type 2 diabetes; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; GLP-1R agonist; GLP-1R agonist clinical trials
- Issue Date
- 2017-03
- Publisher
- apem
- Citation
- Ann Pediatr Endocrinol Metab, v. 22, no. 1, page. 15-26
- Abstract
- The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic β-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.
- URI
- https://e-apem.org/journal/view.php?doi=10.6065/apem.2017.22.1.15https://repository.hanyang.ac.kr/handle/20.500.11754/113430
- ISSN
- 2287-1012; 2287-1292
- DOI
- 10.6065/apem.2017.22.1.15
- Appears in Collections:
- COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
- Files in This Item:
- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.pdfDownload
- Export
- RIS (EndNote)
- XLS (Excel)
- XML